C-X-C chemokine receptor type 4 (CXCR4) constitutes a promising target for tumor diagnosis and therapy. Herein, we evaluate a new 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated CXCR4 antagonist derived from LY2510924, FRM001, and its metal complexes as CXCR4-targeting probes. FRM001 was synthesized by modifying the C-terminus of LY2510924 with maleimido-mono-amide-DOTA via a cysteine linker. FRM001 exhibited CXCR4-specific binding with an affinity similar to that of the parental LY2510924. The binding affinity of FRM001 remained unchanged after complexation with Ga, Lu, and Y. The internalization of 67 Ga-FRM001 into the cells was hardly observed. In mice biodistribution studies, 67 Ga-FRM001 exhibited high accumulation in the tumor and the liver with rapid elimination rates from the blood. The hepatic accumulation of 67 Ga-FRM001 was preferentially and significantly reduced by co-injecting a CXCR4 antagonist, AMD3100. The C-terminalmodified LY2510924 would constitute a versatile scaffold to develop CXCR4-targeting probes or therapeutics for tumor imaging or therapy.
Materials and Methods
Materials. The following CXCR4 antagonists were purchased from commercial sources, as follows: AMD3100 and AMD3465 hexahydrobromide from AdooQ BioScience (Irvine, CA); LY2510924 and BKT140 from MedChemExpress (Monmouth Junction, NJ); and FC131 from FUJIFILM Wako Pure Chemical (Osaka, Japan). Additionally, maleimido-mono-amide-DOTA was obtained from Macrocyclics (Plano, TX), while GaCl 3 , LuCl 3 , and YCl 3 were purchased from Mitsuwa Chemicals (Osaka), Strem Chemicals (Newburyport, MA), and FUJIFILM Wako Pure Chemical, respectively. 67 GaCl 3 was obtained from FUJIFILM Toyama Chemical (Tokyo, Japan), while a 68 Ge/ 68 Ga generator was purchased from ITG Isotope Technologies Garching (Munich, Germany). Iodine-125 ( 125 I)-SDF-1α was purchased from PerkinElmer (Waltham, MA). Other reagents and solvents were purchased from major suppliers and were used without further purification unless indicated.
The radio-TLC analysis was performed on TLC silica gel 60 RP-18 F 254 s (Merck, Darmstadt, Germany) developed with a 1:1 (v/v) mixture of 2 M of ammonium acetate solution and acetone. The strips were analyzed by a GITA Star gamma-TLC scanner (Elysia-Raytest, Straubenhardt, Germany). Radio-HPLC was performed by using the Alliance 2695 HPLC system (Waters, Milford, MA), connected with a 2489 ultraviolet/visible light detector (Waters) and a GABI Star gamma radio detector (Elysia-Raytest). A TSKgel ODS-80Ts QA (5 μm, 4.6 × 250 mm) column (Tosoh, Tokyo) with a flow rate of 1 mL/min was used. Acetonitrile [0.1% trifluoroacetic acid (TFA)] in water (0.1%TFA) was used as the mobile phase with the following multistep gradient: 0-20 min, 20-40% acetonitrile (0.1%TFA); 20-21 min, 40%-100% acetonitrile (0.1%TFA); and 21-30 min, 100% acetonitrile (0.1%TFA).
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOF-MS) was performed on a Microflex system (Bruker, Billerica, MA), while electrospray ionization-mass spectrometry (ESI-MS) was performed using an LCMS-2010EV system (Shimadzu, Kyoto, Japan). Radioactivity was measured using a 2480 WIZERD 2 automatic gamma counter (PerkinElmer). PET images were acquired using an Inveon PET scanner (Siemens, Munich). FRM001 synthesis. The synthesis of FRM001 (cyclo[Phe-Tyr-Lys(iPr)-D -Arg-2-Nal-Gly-D -Glu]-Ly s(iPr)-Cys(maleimido-mono-amide-DOTA)-NH 2, molecular weight: 1,819.13) was entrusted to Scrum (Tokyo) ( Fig. 1) . cyclo[Phe-Tyr-Lys(iPr)-D -Arg-2-Nal-Gly-D -Glu]-Lys(iPr)-Cys-NH 2 (1) was synthesized by solid-phase-peptide synthesis using Fmoc-protected amino acids. Side-chain protecting groups were Fmoc-Cys(Trt)-OH, Fmoc-Lys(Boc, iPr)-OH, Fmoc-D-Glu(OPis)-OH, Fmoc-Gly-OH, Fmoc-2Nal-OH, Fmoc-D-Arg(Pbf)-OH, Fmoc-Lys(Boc, iPr)-OH, Fmoc-Tyr(tBu)-OH, and Fmoc-Phe-OH. Peptides were extended using 4-[2,4-dimethoxyphenyl-N-(9-fluorenylmethoxycarbonyl)aminomethyl]phenoxy resin as a starting material. After constructing the peptide, the cyclization of the peptide was conducted on the resin by removing the OPis-protecting group with 1% TFA/CH 2 Cl 2 and subsequent conjugation with the amine group of N-terminal phenylalanine in the presence of HBTU/HOAt/DIEA. The resulting peptide was treated with a TFA cocktail solution (4.125 mL of TFA, 0.25 mL of H 2 O, 0.375 g of phenol, 0.125 mL of ethanedithiol, and 0.25 mL of thioanisole) to isolate the crude peptide. After purification by reversed-phase (RP)-HPLC, the resulting peptide was conjugated with a maleimido-mono-amide-DOTA to prepare FRM001. 
Radiolabeling of FRM001 with 68
Ga. An eluate from a 68 Ge/ 68 Ga generator was added to a solution of FRM001 dissolved in 1 M of sodium acetate buffer (pH: 5). The resulting solution contained 0.2-0.3 GBq/mL of 68 Ga and 0.01 mM of FRM001 at a pH of 5. The mixture was incubated for 10 min at 95 °C, and radiochemical purity was determined by radio-TLC and radio-HPLC.
Lipophilicity.
A solution of 67 Ga-FRM001 (168 kBq, 56.8 pmol of FRM001) in 0.5 mL of 1-octanol was added to a 0.5 mL solution of phosphate-buffered saline (PBS) (pH 7.4). The mixture was vortexed and rotated at room temperature for 5 min. After centrifugation at 13,000 × g for 5 min, the radioactivity concentrations in samples of both the aqueous and organic phases were determined by using a gamma counter, and the logP ow values were calculated.
Cell culture. A human acute lymphoblastic leukemia cell line, CCRF-CEM 35 , was obtained from the JCRB Cell Bank (JCRB0033; Osaka) and maintained in Roswell Park Memorial Institute 1640 (RPMI-1640; Thermo Fisher Scientific, Waltham) supplemented with 10% (v/v) fetal bovine serum, 100 units/mL of penicillin, and 100 μg/mL of streptomycin. The cells were cultured in a humidified atmosphere of 95% air and 5% carbon dioxide at 37 °C. Passages were performed twice a week.
Competitive binding assay. CCRF-CEM cells and 125 I-SDF-1α were used for the competitive binding assay. The competitive binding assay was performed in a 96-well MultiScreen HTS FB plate (Merck) treated with 0.1% polyethyleneimine. RPMI-1640 containing 1% bovine serum albumin (BSA) and 0.05% Tween20 was used for the assay buffer. Briefly, 200-μL reaction mixtures containing CCRF-CEM (0.5 × 10 6 cells), 125 I-SDF-1α (1 kBq), SDF-1α (0.05 pmol; R&D Systems, Minneapolis, MN), and varying concentrations of CXCR4 antagonists were incubated at room temperature for one hour. After the incubation, the cells were washed three times with the assay buffer, and radioactivity counts of cells were determined with a gamma counter. The IC 50 values were calculated by using GraphPad Prism version 5.04 (GraphPad Software, San Diego, CA).
www.nature.com/scientificreports www.nature.com/scientificreports/ Stability assessment. A 67 Ga-FRM001 solution was diluted 11-fold in human serum (Access Biologicals, Vista, CA), and the solutions were then incubated at 37 °C. After zero, 1.5, and four hours, 0.05-mL aliquots were precipitated and centrifuged at 13,000 × g for 5 min after adding 0.15 mL of acetonitrile (0.1%TFA). The supernatants were then analyzed using radio-HPLC.
Binding assay. The binding assay was performed by using a procedure similar to that of the competitive binding assay. Briefly, 200-μL reaction mixtures containing CCRF-CEM (0.5 × 10 6 cells) and 67 Ga-FRM001 with varying FRM001 concentrations were incubated at 37 °C for one hour in the presence or absence of AMD3100 (0.1 mM). Following the incubation, the cells were washed three times with the assay buffer, and radioactivity counts of the cells were determined with a gamma counter.
Internalization assay. The internalization assay was performed in 1.5-mL centrifuge tubes using RPMI-1640 containing 5% BSA as the binding buffer. Briefly, 200 μL of reaction mixtures containing CCRF-CEM (0.5 × 10 6 cells) and 67 Ga-FRM001 (0.5 pmol of FRM001) were incubated at 37 °C for one hour in the presence or absence of AMD3100 (0.1 mM). After the incubation, the samples were centrifuged at 291 × g for 5 min and the supernatant was removed. To quantify the amounts of internalized radioactivity, the cells were washed twice with an acid wash buffer (0.2 M of glycine, 0.15 M of NaCl; pH: 3.0) and the binding buffer, respectively. To quantify the amounts of total cellular radioactivity, the cells were washed twice with the binding buffer. The radioactivity counts of the cells were determined with a gamma counter. Since the total numbers of cells per tube were varied by the cell washing step, the data were corrected by the number of cells.
Preparation of tumor xenograft model. All Biodistribution study. A biodistribution study was conducted by intravenously administering 67 Ga-FRM001 (0.6 MBq/0.2 nmol FRM001/mouse) in the presence or absence of AMD3100 (0.06 µmol/mouse) into CCRF-CEM tumor-bearing mice. Mice were sacrificed at four hours after the injection. Organs of interest were removed, weighed, and the radioactivity counts were determined using a gamma counter. The biodistribution of each sample was expressed as a percentage of the injected dose per gram of wet tissue weight (%ID/g).
PET imaging study. A PET imaging study was conducted by intravenously administering 68 Ga-FRM001
(2-4 MBq/0.2 nmol FRM001/mouse) in the presence or absence of AMD3100 (0.06 µmol/mouse) into CCRF-CEM tumor-bearing mice. The static PET images were acquired for 15 min at one hour post-injection, using an Inveon PET scanner. After the reconstruction, the images were displayed by using maximum-intensity projection. The mice were anesthetized with isoflurane during the imaging.
Statistical analysis. Biodistribution data and in vitro binding data were statistically analyzed by using
Welch's t-test (two-tailed test). The level of statistical significance was set at p < 0.05. The statistical analysis was performed by using EXSUS version 8.1 (CAC Croit, Tokyo).
Results and Discussion
Design and synthesis of FRM001. FRM001 was designed based on the tentative binding pose of LY2510924 in the CXCR4 ligand-binding cavity 32 . FRM001 was synthesized by conjugating maleimido-mono-amide-DOTA to the C-terminus of LY2510924 through a cysteine linker, followed by the preparative RP-HPLC purification (Fig. 1) . FRM001 was obtained with a purity of 98.48% as confirmed by the analytical HPLC and characterized by the MALDI TOF-MS (see Supplementary Fig. S1 ).
Synthesis of Ga/Lu/Y-FRM001.
Ga-FRM001, Lu-FRM001, and Y-FRM001 were synthesized by incubating 20 equivalents of GaCl 3 , LuCl 3, and YCl 3 over FRM001 for 30 min at 45 °C in sodium acetate buffer (pH: 5). After RP-HPLC, Ga-FRM001, Lu-FRM001, and Y-FRM001 were obtained with purities of 94.23%, 96.24%, and 96.80% as confirmed by the analytical HPLC. All products were characterized by ESI-MS (see Supplementary  Figs S2-S4 ).
Preparation of 67/68 Ga-FRM001. 67 Ga-FRM001 was prepared by incubating FRM001 with 67 GaCl 3 for 10 min at 95 °C in a sodium acetate buffer (pH: 5), followed by the purification through a Sep-Pak C18 column. The radiochemical yield was assessed to be ≥95% by radio-TLC. The radiochemical purity was ≥96% by radio-TLC and ≥97% by radio-HPLC (see Supplementary Fig. S5 ). The specific activity was 3 MBq/nmol. 68 Ga-FRM001 was prepared by incubating FRM001 with 68 GaCl 3 for 10 min at 95 °C in sodium acetate buffer (pH: 5) without post-labeling purification to shorten the preparation time. The radiochemical purity was assessed to be ≥98% by radio-TLC and ≥95% by radio-HPLC (see Supplementary Fig. S6 ). The specific activity was 19-20 MBq/nmol. www.nature.com/scientificreports www.nature.com/scientificreports/ CXCR4 binding affinity. Since the purpose of this study was to assess in vivo accumulation to CXCR4-expressing cells, the apparent binding affinities were determined at 37 °C. To compare the affinity for CXCR4 under the present study, the binding affinities of the reference compounds, LY2510924, FC131, BKT140, AMD3465, and AMD3100 were also determined under similar conditions. The half-maximal inhibitory concentration (IC 50 ) values of FRM001, its Ga-, Lu-, and Y-complexes, and other CXCR4 antagonists were determined with CCRF-CEM cells expressing endogenous CXCR4 34 . The displacement of 125 I-SDF-1α bound to the CXCR4 with the compounds was also evaluated in the presence of 0.25 nM of SDF-1α. Table 1 summarizes the IC 50 values of the compounds. The competitive binding curves are presented in Supplementary Fig. S7 . FRM001 showed improved CXCR4 affinity as compared with FC131 37 , AMD3100 38,39 , AMD3465 40 , and BKT140 41, 42 , which are reported to be potent CXCR4 antagonists.
Lipophilicity (logP ow
The similar IC 50 values between FRM001 and LY2510924 indicated that the DOTA conjugation through the C-terminus of LY2510924 via a cysteine linker preserved the inherent affinity for CXCR4. The binding affinity of FRM001 also remained unchanged after complexation with a metal ion (Ga 3+ , Lu 3+ , or Y 3+ ). In contrast, the complexation of different metal ions with pentixafor or pentixather led to significant changes in CXCR4 affinities 30, 31 . These results suggested that the 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A) moiety in FRM001 would be well-separated from the CXCR4 binding motif of the molecule via a cysteine linker, which would account for the tolerance of FRM001 to the complexation reaction with the three metal ions. Since DO3A forms kinetically inert complexes with 67/68 Ga, 177 Lu, 90 Y, 111 In, and 225 Ac 33,43-45 , FRM001 would constitute a useful scaffold upon which to develop a variety of theranostic pairs combined with the metallic radionuclides.
CXCR4-specific binding and internalization.
The CXCR4 specificity of 67 Ga-FRM001 was determined with CCRF-CEM cells in the presence of a CXCR4 antagonist, AMD3100. The internalization activity was also measured by washing the cells with an acid buffer to remove the receptor-bound 67 Ga-FRM001 46 . 67 Ga-FRM001 was bound to CCRF-CEM cells in a dose-dependent manner and exhibited high specificity for CXCR4 ( Fig. 2 and Supplementary Fig. S9 ). The majority of 67 Ga-FRM001 bound to cells via CXCR4 was not internalized and remained at the cell membrane (Fig. 3) . The complete inhibition of internalized 67 Ga-FRM001 by AMD3100 (Fig. 3) also suggested that the internalization of 67 Ga-FRM001 would only proceed after binding to CXCR4 on the cells. Similar results were observed with another antagonistic CXCR4 probe 47 Biodistribution of 67 Ga-FRM001. The biodistribution of 67 Ga-FRM001 was assessed in CCRF-CEM tumor-bearing mice. Each animal was given 67 Ga-FRM001 (0.6 MBq/0.2 nmol FRM001/mouse, intravenous injection) and sacrificed at four hours post-injection. 67 Ga-FRM001 was also administered to another group of animals along with AMD3100 (0.06 µmol/mouse). These results are summarized in Table 2 . 67 Ga-FRM001 showed a high rate of accumulation in the tumor and rapid elimination rate from the blood. As a result, 67 Ga-FRM001 exhibited a tumor-to-blood ratio of 59 at four hours post-injection. As shown in Fig. 3 , 67 Ga-FRM001 possesses an antagonist profile with a high binding affinity to the target molecule. Thus, 67 Ga-FRM001 constitutes another example that supports the paradigm shift from agonists to antagonists as radioligands for in vivo targeting with the peptide-based probe 31, 49, 50 . The accumulation in the spleen, thymus, and bone would be attributable to physiological expression of CXCR4 in these tissues as reported previously 51 , which was supported by the significant reduction in the radioactivity levels of these tissues following AMD3100 co-injection (Table 2 ). 67 Ga-FRM001 also displayed a high hepatic accumulation similar to those levels of other CXCR4-targeting probes such as 68 Ga-NOTA-NFB 9,52 , 64 Cu-AMD3100 10, 53 , and 177 Lu-pentixather 14, 31 . The AMD3100 co-injection significantly reduced the hepatic radioactivity levels ( Table 2 ) similar to in the cases of other CXCR4-targeting probes. Since CXCR4 is constitutively expressed in the sinusoidal endothelial cells of the murine liver 54 , the CXCR4-mediated accumulation would be partially involved in the hepatic accumulation. www.nature.com/scientificreports www.nature.com/scientificreports/ However, the CXCR4 expression levels in the liver are lower than those of the spleen, thymus, and thymus 51 . The accumulation of 67 Ga-FRM001 in the tumor was much less inhibited by the AMD3100 co-injection when compared with that in the liver ( Table 2) . Considering significantly higher binding affinity of Ga-FRM001 to CXCR4 than to AMD3100, the hepatic accumulation of 67 Ga-FRM001 would be attributable to another yet-unknown mechanism, as also reported in other CXCR4-targeting probes 7, 31, 55 . Recently, the involvement of organic cation transporters has been discussed as a hepatic accumulation mechanism 56 . The blockage of hepatic accumulation of 67 Ga-FRM001 by AMD3100 co-injection would facilitate the renal excretion of free 67 Ga-FRM001 in plasma, which was reflected in a slight but significant increase in the renal radioactivity levels ( Table 2) . Similar results were observed in radiolabeled CXCR4 probes 31, 57 and a 99m Tc-labeled bivalent RGD probe 58 .
PET imaging study. Figure 5 shows representative PET images in CCRF-CEM tumor-bearing mice after the administration of 68 Ga-FRM001 (2-4 MBq/0.2 nmol FRM001/mouse, intravenous injection) in the presence or absence of AMD3100 (0.06 µmol/mouse). PET images were acquired at one hour post-injection. Table 2 . Biodistribution of 67 Ga-FRM001 (0.6 MBq/0.2 nmol FRM001/mouse, intravenous injection) in CCRF-CEM tumor-bearing mice at four hours post-injection. The data are shown as the mean percentages of the injected dose per gram of wet tissue weight (%ID/g) ± standard deviations (for each group, n = 5 mice). a AMD3100 was co-injected (0.06 µmol/mouse). b A significant difference (p < 0.05) was determined by performing Welch's t-test. 
